---
title: "LYE plans to sell no more than 592,400 repurchased shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252054814.md"
description: "According to the Zhitong Finance APP, LYE announced that the company's board of directors agreed to reduce its holdings through centralized bidding trading for the purpose of maintaining the company's value and shareholder rights, and will sell all repurchased shares in accordance with relevant regulations, with a planned reduction of no more than 592,400 shares"
datetime: "2025-08-07T13:19:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252054814.md)
  - [en](https://longbridge.com/en/news/252054814.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252054814.md)
generator: "portal-rs"
---

# LYE plans to sell no more than 592,400 repurchased shares

According to the Zhitong Finance APP, LYE (301389.SZ) announced that the company's board of directors agreed to reduce its holdings through centralized bidding trading for the purpose of maintaining the company's value and shareholder rights, and plans to sell part of the repurchased shares in accordance with relevant regulations, with a proposed reduction of no more than 592,400 shares

### Related Stocks

- [301389.CN](https://longbridge.com/en/quote/301389.CN.md)

## Related News & Research

- [METALS-Copper firms as metal earmarked to exit LME triggers buying](https://longbridge.com/en/news/296765325.md)
- [EDM Announces Results of the Annual General Meeting | EDMFF Stock News](https://longbridge.com/en/news/296781083.md)
- [10:41 ETDeepCura Unveils the Electronic Health Workforce (EHW) -- the Step Beyond the EHR](https://longbridge.com/en/news/296803806.md)
- [Flexcon Announces Global Relaunch of PharmCal® BioMark with ISEGA Certification](https://longbridge.com/en/news/296800649.md)
- [09:02 ETIMAGE Skincare Expands Its GLP-1-Targeted Skincare Innovation with New VOL.U.LIFT™ BODY Sculpt + Firm Treatment Complex](https://longbridge.com/en/news/296792631.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**